Equities Analysts Set Expectations for BCRX FY2026 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for BioCryst Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the biotechnology company will earn $0.21 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $20.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.

Several other brokerages have also recently commented on BCRX. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Needham & Company LLC upped their price target on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Royal Bank of Canada restated an "outperform" rating and issued a $13.00 price objective (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price for the company. Finally, JPMorgan Chase & Co. upped their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, BioCryst Pharmaceuticals has an average rating of "Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Stock Down 0.3%

NASDAQ BCRX traded down $0.03 on Tuesday, reaching $10.37. The stock had a trading volume of 2,660,575 shares, compared to its average volume of 3,043,496. The stock has a fifty day moving average price of $9.37 and a two-hundred day moving average price of $8.39. BioCryst Pharmaceuticals has a 12-month low of $5.92 and a 12-month high of $11.31. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -17.00 and a beta of 1.11.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of BCRX. Millennium Management LLC grew its stake in BioCryst Pharmaceuticals by 382.6% in the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock worth $28,597,000 after acquiring an additional 3,022,769 shares during the period. Vanguard Group Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Eversept Partners LP grew its position in shares of BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after purchasing an additional 1,444,907 shares during the period. Nuveen LLC acquired a new position in BioCryst Pharmaceuticals in the first quarter valued at $10,677,000. Finally, Jupiter Asset Management Ltd. lifted its position in BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock worth $16,117,000 after buying an additional 971,040 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.